Hims & Hers Health (HIMS) shares were down more than 3.5% in Friday's premarket activity after closing down 7.7% on Thursday following a US Food and Drug Administration determination that a shortage of Eli Lilly's (LLY) popular weight loss drug tirzepatide has ended.
Hims & Hers Health was allowed to produce its version of the drug as long as the FDA determined there was a shortage.
The FDA said in a letter on Thursday that "the tirzepatide injection product shortage is resolved."
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。